Technical Resources International Inc. - Bethesda MD(8 months 4 weeks ago)
Founded in 1979, Technical Resources International, Inc. (TRI) provides a unique range of support services in the areas of Communications, Health and Information Technology to both private industry and government agency clients. TRI is currently seeking a Quality Assurance (QA) Compliance Specialist to join our...
Several pharmaceutical companies in 2011 and 2012 are experiencing the ravages of patent expirations; but some experts believe that the worst may be over, and executives are more confident about the future.Read more
The leaders of Bristol-Myers Squibb are hoping that a group of fast-growing products and an aggressive strategy of acquisition and partnership can keep the company afloat after the loss of its most successful brand.
The world’s largest and most diverse maker of healthcare products is seeking to improve manufacturing problems and capitalize on new drugs and indications; the Synthes acquisition is providing positive effects.
After generating company-record sales in 2011, to help offset the patent-protection loss of its top-selling product, Novartis is capitalizing on growth from other billion-dollar brands and the Alcon business while awaiting a new generation of drug and vaccine blockbusters.
In 2011, Pfizer revamped its R&D program to a “precision medicine” approach and prepared for the patent expiry of Lipitor; the company also launched an innovative new cancer drug and met its revenue goals.